The Official Journal of EuroPCR and the European Association of Percutaneous Coronary Interventions (EAPCI)

Editorial

NVT ALLEGRA transcatheter heart valve for valve-in-valve procedures in failing surgical aortic bioprostheses: let us wait and see

EuroIntervention 2019;15:e739-e741. DOI: 10.4244/EIJV15I9A137

1. Division of Cardiology, Department of Medicine, University of Verona, Verona, Italy


Initially performed as an off-label procedure1 in the context of failing surgical aortic valves, valve-in-valve (ViV) transcatheter aortic valve implantation (TAVI), over the last decade, has gained widespread application in the management of increasingly complex cases deemed at high risk for traditional open chest surgery. This technique presents some potential complications, such as ostial coronary obstruction (e.g., Mitroflow; Sorin Group, Saluggia, Italy), and the risk of technical failure due to patient-prosthesis mismatch leading to excessively high post-procedural gradients, particularly in small bioprostheses (<23 mm)2. Until now, the majority of ViV procedures have been performed using Medtronic or Edwards ...

Sign in to read and download the full article

Forgot your password?
No account yet? Sign up for free!
Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

Read next article

Ruptured and healed atherosclerotic plaques: breaking bad?